| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | JAG2 |
| Uniprot No | Q9Y219 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 121-210aa |
| 氨基酸序列 | AGGDQDPGLVVIPFQFAWPRSFTLIVEAWDWDNDTTPNEELLIERVSHAG MINPEDRWKSLHFSGHVAHLELQIRVRCDENYYSATCNKF |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于JAG2重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**: *"Recombinant expression and functional characterization of human JAG2 in Notch signaling activation"*
**作者**: Smith A, et al.
**摘要**: 研究报道了通过哺乳动物表达系统(HEK293细胞)重组表达人源JAG2蛋白，验证其通过Notch信号通路调控肿瘤细胞增殖和迁移的活性，并建立体外配体-受体结合实验模型。
---
2. **文献名称**: *"Structural insights into JAG2-Notch3 interaction using purified recombinant extracellular domains"*
**作者**: Lee H, et al.
**摘要**: 利用昆虫细胞表达系统制备JAG2胞外区重组蛋白，结合X射线晶体学解析其与Notch3受体复合物的结构，揭示二者特异性结合的分子机制，为靶向药物设计提供依据。
---
3. **文献名称**: *"JAG2 recombinant protein enhances stemness in colorectal cancer organoids via Notch pathway"*
**作者**: Wang Y, et al.
**摘要**: 通过原核系统(E. coli)表达并纯化功能性JAG2重组蛋白，发现其可激活结直肠癌类器官中的Notch信号通路，促进肿瘤干细胞特性，提示JAG2在癌症治疗中的潜在靶点价值。
---
(注：以上文献为示例性内容，实际文献需通过PubMed/Google Scholar等平台检索确认。)
**Background of JAG2 Recombinant Protein**
JAG2 (Jagged Canonical Notch Ligand 2) is a transmembrane protein belonging to the Delta/Serrate/LAG-2 (DSL) family of ligands that activate the Notch signaling pathway, a highly conserved system critical for cell-cell communication. This pathway regulates diverse biological processes, including cell differentiation, proliferation, apoptosis, and tissue homeostasis. JAG2 specifically interacts with Notch receptors (Notch1-4) to initiate proteolytic cleavage events, releasing the Notch intracellular domain (NICD), which translocates to the nucleus to modulate gene expression.
The JAG2 gene is implicated in developmental processes, such as limb formation, hematopoiesis, and neural crest cell migration. Dysregulation of JAG2-Notch signaling has been linked to pathological conditions, including cancers (e.g., breast, pancreatic, and leukemia), where it often promotes tumor progression, angiogenesis, and chemoresistance. Its role in immune regulation and stem cell maintenance also makes it a target for therapeutic exploration.
Recombinant JAG2 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce soluble, bioactive fragments, typically containing the extracellular domain responsible for receptor binding. This protein retains functional epitopes, enabling studies on Notch pathway activation, ligand-receptor specificity, and downstream signaling mechanisms. Researchers utilize JAG2 recombinant protein in vitro (cell-based assays) and in vivo (animal models) to investigate its role in development, disease, and potential as a diagnostic or therapeutic tool. Its applications extend to drug screening, antibody development, and understanding resistance mechanisms in Notch-targeted therapies.
Overall, JAG2 recombinant protein serves as a vital tool for dissecting the complexity of Notch signaling and advancing translational research in oncology and regenerative medicine.
×
